Long term efficacy and persistence of biologics therapy in Crohn’s disease in multiracial Asian country

• Main Authors: Xin Hui, Khoo, Nik Muhamad Affendi, Nik Arsyad, Leow, Alex Hwong Ruey, Hilmi, Ida Normiha
• Format: Article
• Language: English
• Published: Wiley 2023
• Subjects: R Medicine (General)
• Online Access: http://irep.iium.edu.my/110173/6/110173_Long%20term%20efficacy%20and%20persistence%20of%20biologics%20therapy.pdf; http://irep.iium.edu.my/110173/; https://onlinelibrary.wiley.com/doi/10.1111/jgh.16422; https://doi.org/10.1111/jgh.16422
• Institution: Universiti Islam Antarabangsa Malaysia

Background and Aim:Biologic therapy is an effective treatment inmoderate-to-severe Crohn disease (CD); however, there is a lack of head-to-head study to the compare efficacy between available biologic therapy.We sought to determine efficacy and persistence of the currently availabletherapy in biologic naïve CD patients in our center. Methods:A retrospective, single-center study was conducted where all bi-ologic naïve CD patients who were started on biologics therapy were re-cruited. Demographic and baseline clinical characteristic data wascollected. Clinical remission and persistence up to 3 years after startingtreatment were analyzed. Results:A total of 118 patients were recruited into this study. Mean agewas 30.6 ± 10.9 year old. 61% (n= 72) were male and 39% (n= 46) werefemale. Ethnicity, Indian 44.9% (n= 53), Chinese 34.7% (n= 41) and Ma-lay 19.5% (n= 23). Mean disease duration was 7.57 ± 5.1 years. Locationof disease was as follows; 34.7% (n= 41) Ileal, 28.8% (n= 34) colon,32.2% (n= 38) ileocolon and 4.2% (n= 5) isolated upper GI. Majorityhad non-penetrating non-stricturing disease 70.3% (n= 83) followed by17.8% (n= 21) stricturing disease and 11.9% (n= 14) penetrating disease.27.1% (n= 32) had perianal disease. The median duration of biologic ther-apy was 26.5 ± 26.8 months. Clinical remission and persistence of biologictherapy are shown in Figure 1. Conclusion:In this study, infliximab and ustekinumab have significantlyhigher efficacy and persistence as compared to adalimumab andvedolizumab although this data has to be interpreted with caution due tothe unequal number of patients in each group and retrospective nature ofstudy.